• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用现代风险引擎和机器学习/人工智能预测糖尿病并发症:以 BRAVO 模型为重点。

Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model.

机构信息

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, United States of America.

Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States of America.

出版信息

J Diabetes Complications. 2022 Nov;36(11):108316. doi: 10.1016/j.jdiacomp.2022.108316. Epub 2022 Oct 3.

DOI:10.1016/j.jdiacomp.2022.108316
PMID:36201893
Abstract

Management of diabetes requires a multifaceted approach of risk factor reduction; through management of risk factors such as glucose, blood pressure and cholesterol. Goals for these risk factors often vary and guidelines suggest that this is based on patient characteristics and need to be individualized. Evaluating risk is therefore critically important to determine goals and choose appropriate treatments. A risk engine is an analytic tool that collects a large amount of population data allowing the simulation of the progression of diabetes with set equations over a period of time. Recently, a number of data cohorts have become available, leading to the development of newer risk engines that are more dynamic and generalizable. An example is the Building, Relating, Assessing, and Validating Outcomes in (BRAVO) diabetes model which was built on the ACCORD trial database. It is capable of accurately predicting diabetes comorbidities in an international population based on calibration with international clinical trial data. It has potential uses in risk stratification of patients, evaluation of interventions and calculation of their long term cost effectiveness. Recently, it has been used to simulate long term outcomes based on short term data, using difference modelling scenarios.

摘要

糖尿病的管理需要采取多方面的方法来降低风险因素;通过管理血糖、血压和胆固醇等风险因素。这些风险因素的目标往往因患者的特点和需求而异,因此需要个体化。评估风险对于确定目标和选择适当的治疗方法至关重要。风险引擎是一种分析工具,它收集大量人群数据,允许通过设定的方程在一段时间内模拟糖尿病的进展。最近,出现了许多数据队列,导致更具动态性和通用性的新型风险引擎的发展。例如,基于 ACCORD 试验数据库构建的 Building, Relating, Assessing, and Validating Outcomes in (BRAVO) 糖尿病模型。它能够根据与国际临床试验数据的校准,准确预测国际人群中的糖尿病合并症。它在患者风险分层、干预效果评估和长期成本效益计算方面具有潜在的用途。最近,它被用于使用差异建模方案,根据短期数据模拟长期结果。

相似文献

1
Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model.利用现代风险引擎和机器学习/人工智能预测糖尿病并发症:以 BRAVO 模型为重点。
J Diabetes Complications. 2022 Nov;36(11):108316. doi: 10.1016/j.jdiacomp.2022.108316. Epub 2022 Oct 3.
2
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors.使用 BRAVO 风险引擎预测钠-葡萄糖协同转运蛋白 2 抑制剂临床试验中的心血管结局。
Diabetes Care. 2020 Jul;43(7):1530-1536. doi: 10.2337/dc20-0227. Epub 2020 Apr 28.
3
Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO).美国新型糖尿病进展和死亡率风险引擎:构建、关联、评估和验证结果(BRAVO)。
Pharmacoeconomics. 2018 Sep;36(9):1125-1134. doi: 10.1007/s40273-018-0662-1.
4
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Data-driven modeling and prediction of blood glucose dynamics: Machine learning applications in type 1 diabetes.基于数据驱动的血糖动力学建模与预测:机器学习在 1 型糖尿病中的应用。
Artif Intell Med. 2019 Jul;98:109-134. doi: 10.1016/j.artmed.2019.07.007. Epub 2019 Jul 26.
8
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.瑞格列奈:对其在2型糖尿病治疗中应用的药物经济学综述
Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005.
9
Using Artificial Intelligence to Develop a Multivariate Model with a Machine Learning Model to Predict Complications in Mexican Diabetic Patients without Arterial Hypertension (National Nested Case-Control Study): Metformin and Elevated Normal Blood Pressure Are Risk Factors, and Obesity Is Protective.利用人工智能开发机器学习模型的多元模型,以预测墨西哥无动脉高血压糖尿病患者的并发症(全国巢式病例对照研究):二甲双胍和正常血压升高是危险因素,而肥胖是保护因素。
J Diabetes Res. 2023 Feb 16;2023:8898958. doi: 10.1155/2023/8898958. eCollection 2023.
10
Artificial Intelligence (AI) based machine learning models predict glucose variability and hypoglycaemia risk in patients with type 2 diabetes on a multiple drug regimen who fast during ramadan (The PROFAST - IT Ramadan study).基于人工智能的机器学习模型预测接受多种药物治疗且在斋月期间禁食的 2 型糖尿病患者的血糖变异性和低血糖风险(PROFAST-IT 斋月研究)。
Diabetes Res Clin Pract. 2020 Nov;169:108388. doi: 10.1016/j.diabres.2020.108388. Epub 2020 Aug 26.

引用本文的文献

1
Barriers and Facilitators to Artificial Intelligence Implementation in Diabetes Management from Healthcare Workers' Perspective: A Scoping Review.从医护人员视角看人工智能在糖尿病管理中应用的障碍与促进因素:一项范围综述
Medicina (Kaunas). 2025 Aug 1;61(8):1403. doi: 10.3390/medicina61081403.
2
Artificial Intelligence in Diabetes Care: Applications, Challenges, and Opportunities Ahead.糖尿病护理中的人工智能:应用、挑战与未来机遇
Endocr Pract. 2025 Jul 17. doi: 10.1016/j.eprac.2025.07.008.
3
Capturing the Additional Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists Beyond the Control of Traditional Risk Factors in People With Diabetes.
在糖尿病患者中,捕捉钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂和胰高血糖素样肽-1(GLP-1)受体激动剂在控制传统危险因素之外的额外心血管益处。
Value Health. 2025 May;28(5):762-768. doi: 10.1016/j.jval.2025.01.015. Epub 2025 Feb 6.
4
Value-Based Pricing and Its Implications for the Newly Announced Medicare Negotiated Price Under the Inflation Reduction Act.基于价值的定价及其对根据《降低通胀法案》新公布的医疗保险协商价格的影响。
Diabetes Care. 2025 Apr 1;48(4):e44-e46. doi: 10.2337/dc24-2403.
5
An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.使用 BRAVO 糖尿病模型对胰岛素甘精 300 单位/毫升与胰岛素甘精 100 单位/毫升的终生成本效益进行探索性分析。
Diabet Med. 2024 May;41(5):e15303. doi: 10.1111/dme.15303. Epub 2024 Mar 12.
6
Improving Physical, Physiological, and Psychological Health Outcomes in Patients with Diabetic Foot Ulcers - State of the Art.改善糖尿病足溃疡患者的身体、生理和心理健康结局——最新进展
Clin Cosmet Investig Dermatol. 2023 Dec 12;16:3547-3560. doi: 10.2147/CCID.S333660. eCollection 2023.
7
AI-supported insulin dosing for type 2 diabetes.人工智能支持的2型糖尿病胰岛素给药
Nat Med. 2023 Oct;29(10):2414-2415. doi: 10.1038/s41591-023-02573-4.
8
Theranostic roles of machine learning in clinical management of kidney stone disease.机器学习在肾结石疾病临床管理中的诊疗作用。
Comput Struct Biotechnol J. 2022 Dec 5;21:260-266. doi: 10.1016/j.csbj.2022.12.004. eCollection 2023.